Cyclerion was spun-off from Ironwood Pharmaceutics in April 2019 • Program Leader of multi-disciplinary team responsible for identifying a lung-targeted aerosolized small molecule stimulator of soluble guanylate cyclase for treatment of rare pulmonary diseases; advanced lead molecule into late stage preclinical assessment • Led effort with commercial and clinical research teams to identify pulmonary disease opportunities and to develop clinical/translational strategy

• Program Leader of discovery phase pulmonary inflammation/fibrosis small molecule program • Drove the development of inhalation dosing capabilities and expertise at Ironwood• Co-leader of company-wide Translational Science Team, responsible for identifying biomarker panels for ongoing clinical studies and for executing on biomarker strategy• Co-led cross-company effort to characterize the company’s primary drug target, soluble guanylate cyclase; responsible for driving mechanistic studies, genetic validation, and interactions with academic collaborators• Led FTE-intensive, collaborative program with Protagonist Therapeutics in the identification of peptide-based cytokine therapeutics for auto-immune indications• Leader of Peptide Therapeutic Team, responsible for identifying novel, peptide-based therapeutic targets and opportunities• Spearheaded the establishment of an integrated compound management function • Established two successful, recurring research forums that bring together academic and industry researchers in two research areas: peptide-based therapeutics and cyclic GMP-based research (both are still ongoing)

• Head of Biology; successfully built a high functioning team with expertise in in vitro pharmacology, in vivo pharmacology, and mechanistic biology• Member of Executive Management Team that set strategy and tactics for the company and interfaced with the Board of Directors and Scientific Advisory Board• Facilitated creation of the strategic direction and vision of the company - positioned Anchor as a cutting edge GPCR company focused on the development of allosteric modulators and biased ligands• Made numerous presentations at scientific conferences, business development events and Board meetings. Led the company to its first scientific publication and authored several high impact papers. Established research collaborations with a number of the leading GPCR scientists in the field• Oversaw multiple drug discovery programs including projects in diabetes, inflammation, stem cell recruitment, and cardiovascular disease. Led several successful projects within J&J alliance, including an oncology programSenior Director, Biology (August 2009-January 2011)

• Member of Executive Management Team• Executive Director of Biology Department; built high functioning group responsible for conducting in vitro and in vivo studies and development of models for obesity, diabetes, heart failure and sexual dysfunction• Led successful effort to engineer out known side effect profiles (sexual response and hemodynamic) from melanocortin agonist drug candidates for obesity• Co-chaired alliance program with Astra-Zeneca resulting in the successful identification of AZD2820, a peptide-based melanocortin receptor agonist, which entered into Clinical Trials for the treatment of obesity • Drove pharmacology, safety and biomarker studies to support development of PL-3994, a natriuretic peptide receptor A (NPRA) agonist in clinical trials for refractory hypertension

BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTESenior Principal Scientist, Metabolic and Cardiovascular Drug Discovery (2005 – June 2007)Principal Scientist, Metabolic and Cardiovascular Drug Discovery (2003 - 2005) Senior Research Investigator II, Cardiovascular Drug Discovery (2000 - 2003)Senior Research Investigator I, Cardiovascular Drug Discovery (1997 - 2000)Research Investigator II, Cardiovascular Drug Discovery (1993 - 1997)• Chaired a multi-disciplinary discovery team of 40+ members that successfully identified and advanced a Cannabinoid-1 Receptor small molecule clinical candidate. Member of the Development team that advanced the Cannabinoid antagonist SLV-319 into Ph IIb clinical trials for obesity• Led an Institute-wide GPCR Target Team that was rewarded with a prestigious Triumph Award for its many successes, including establishment and implementation of strategies for orphan receptor drug discovery, focused library development, evaluation of technologies for in-licensing, and the realization of a significant amount of intellectual property • Led a team that successfully identified a potent, selective and in vivo active agonist for the melanocortin-1 receptor for vascular inflammation; published a seminal paper on this effort• In vitro pharmacology leader of a Dual Endothelin/Angiotensin II Receptor Program that successful progressed a candidate into the clinic for hypertension and heart failure• Led multiple early phase programs focused on developing small molecule antagonists of chemokine receptors• Provided molecular biology expertise to an organization that lacked molecular capabilities, including cloning and expression studies